We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current TYP market cap is 42.14M. The company's latest EPS is AUD -0.0054 and P/E is -7.41.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 2.67M | 4.19M | 4.21M | 3.39M | 1.11M |
| Operating Income | -5.34M | -8.48M | -10.01M | -6.82M | -5.61M |
| Net Income | -5.28M | -8.47M | -10.08M | -7.13M | -6.14M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 6.54M | 21.46M | 13.61M | 5.88M | 7.45M |
| Total Liabilities | 1.53M | 2.59M | 4.81M | 1.75M | 1.83M |
| Total Equity | 5.02M | 18.87M | 8.81M | 4.13M | 5.62M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -6.7M | -7.83M | -8.53M | -3.85M | -6M |
| Investing | -950k | -1.8M | -1.24M | -277k | 1.68M |
| Financing | 4.97M | 20.61M | 1.88M | 919k | 9.27M |
| Market Cap | 42.14M |
| Price to Earnings Ratio | -7.41 |
| Price to Sales Ratio | 40 |
| Price to Cash Ratio | 8.51 |
| Price to Book Ratio | 8.11 |
| Dividend Yield | - |
| Shares Outstanding | 1.14B |
| Average Volume (1 week) | 1.31M |
| Average Volume (1 Month) | 2.12M |
| 52 Week Change | 42.31% |
| 52 Week High | 0.057 |
| 52 Week Low | 0.017 |
| Spread (Intraday) | 0 (7.89%) |
| Company Name | Tryptamine Therapeutics Ltd |
| Address |
suite 201 melbourne, victoria |
| Website | https://tryptherapeutics.com/ |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
